Li Xiaodan, Qiao Zhi, Long Xing, Wei Jinxiong, Cheng Yong
Department of Oral Maxillofacial Surgery, College of Stomatology, Wuhan University, Key Laboratory for Oral Biomedical Engineering, Ministry of Education, Wuhan, Hubei 430079, PR China.
Br J Oral Maxillofac Surg. 2005 Dec;43(6):513-5. doi: 10.1016/j.bjoms.2004.11.020. Epub 2005 Sep 26.
The aim of this study was to discover the clinical value of the tumour marker AMDL DR-70 in a group of patients with cancer of the tongue. Serum concentrations of AMDL DR-70 were estimated by enzyme linked immuno-sorbent assay in 52 patients with carcinoma of the tongue and compared with 40 controls and 42 patients with benign lesions in the tongue. Thirty-nine patients with carcinoma of the tongue had results above 6 mg/L (75%), compared with 3/40 (7%) in healthy controls and 4/42 (10%) in those with benign tumours. The concentration of AMDL DR-70 in serum correlated significantly with 3-year survival.
本研究的目的是发现肿瘤标志物AMDL DR-70在一组舌癌患者中的临床价值。通过酶联免疫吸附测定法对52例舌癌患者的血清AMDL DR-70浓度进行了估计，并与40例对照者和42例舌部良性病变患者进行了比较。39例舌癌患者的结果高于6mg/L（75%），而健康对照者中为3/40（7%），良性肿瘤患者中为4/42（10%）。血清中AMDL DR-70的浓度与3年生存率显著相关。
